Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics

Pharmacoepidemiology and Drug Safety
Robert M Califf, CERTs Benefit Assessment Workshop Participants

Abstract

The ability to manage risk depends critically on an understanding of the degree to which a known risk is balanced by the probability of a clinical benefit. Despite the massive emphasis on risk and risk management in the past few years and the long-term focus on defining benefit in the regulatory system, considerable uncertainty remains about the methods of defining benefit and how to operationalize this knowledge. In this 'think tank,' part of a larger series on risk management, issues were divided into those that can be identified before a study is initiated, those that commonly arise after a study is completed, biomarkers and surrogates, use of benefit findings in defining quality and performance indicators, implementation of findings into health systems and formularies, and methods of comparative trials. Key categories for the establishment of a research agenda to fill in gaps in our understanding of assessing benefit were developed by the group.

References

Jul 3, 1991·JAMA : the Journal of the American Medical Association·S YusufH A Tyroler
Jan 1, 1990·Journal of the American College of Cardiology·M A HlatkyD B Pryor
Jun 30, 1988·The New England Journal of Medicine·A LaupacisR S Roberts
Jul 1, 1995·Annals of Internal Medicine·R G Evans
Jan 1, 1995·Journal of Clinical Epidemiology·R PetoR Gray
Oct 1, 1993·Journal of General Internal Medicine·D J MalenkaJ M Ross
Apr 1, 1996·Medical Decision Making : an International Journal of the Society for Medical Decision Making·D Hadorn
Oct 1, 1996·Annals of Internal Medicine·T R Fleming, D L DeMets
Oct 23, 1997·Circulation·A SimonJ Levenson
Oct 8, 1999·Lancet·C D FurbergB M Psaty
Jun 22, 2000·The New England Journal of Medicine·K Benson, A J Hartz
Jun 22, 2000·The New England Journal of Medicine·J ConcatoR I Horwitz
Jul 14, 2000·Clinical Cardiology·C D Furberg
May 10, 2001·Proceedings of the National Academy of Sciences of the United States of America·K G Manton, X Gu
Aug 10, 2001·JAMA : the Journal of the American Medical Association·P Y LeeE D Peterson
Aug 30, 2001·American Heart Journal·H WedelUNKNOWN MERIT-HF Study Group
Jan 5, 2002·The New England Journal of Medicine·J N CohnUNKNOWN Valsartan Heart Failure Trial Investigators
Jul 3, 2002·Annals of Internal Medicine·Edward J Huth, Kathleen Case
Jul 19, 2002·JAMA : the Journal of the American Medical Association·Jacques E RossouwUNKNOWN Writing Group for the Women's Health Initiative Investigators
Aug 21, 2002·Circulation·Robert M Califf, David L DeMets
Nov 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer L MalinRobert H Brook
Dec 12, 2002·Journal of the American College of Cardiology·Robert M CaliffUNKNOWN American Heart Association
Jan 10, 2003·Statistics in Medicine·Mark RothmannHsiao-Hui Tsou
Mar 14, 2003·JAMA : the Journal of the American Medical Association·Nancy S SungDavid Rimoin
Mar 20, 2003·Pharmacoepidemiology and Drug Safety·Robert Gross, Brian L Strom
May 8, 2003·Pharmacoepidemiology and Drug Safety·William H Campbell, Robert M Califf
May 17, 2003·Clinical Therapeutics·Kevin P Weinfurt
May 27, 2003·American Heart Journal·Kenneth Dickstein
Aug 9, 2003·Expert Opinion on Drug Safety·Terry A Jacobson
Sep 19, 2003·Lancet·Marc A PfefferUNKNOWN CHARM Investigators and Committees
Sep 23, 2003·Controlled Clinical Trials·Mike R SatherUNKNOWN Department of Veterans Affairs Cooperative Studies Program
Sep 25, 2003·JAMA : the Journal of the American Medical Association·Sean R TunisCarolyn M Clancy
Sep 27, 2003·BMJ : British Medical Journal·Gerd Gigerenzer, Adrian Edwards
Nov 12, 2003·The New England Journal of Medicine·Marc A PfefferUNKNOWN Valsartan in Acute Myocardial Infarction Trial Investigators

❮ Previous
Next ❯

Citations

Sep 23, 2008·American Journal of Therapeutics·Paul E StangKathleen Gondek
Sep 21, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Peter G M MolSabine M J M Straus
May 22, 2010·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Peter G M MolFlora M Haaijer-Ruskamp
Apr 7, 2012·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Sigrid PieningPeter G M Mol
May 6, 2015·British Journal of Clinical Pharmacology·Francesco BellantiOscar Della Pasqua
Apr 20, 2011·British Journal of Clinical Pharmacology·Arna H ArnardottirPeter G M Mol
Sep 28, 2015·The International Journal of Risk & Safety in Medicine·Joel Lexchin
Apr 24, 2010·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jeff J GuoDennis W Raisch
Mar 1, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·Surbhi SainiAmy L Dunn
Dec 12, 2007·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Stella C Wong, James R Roberts
Feb 16, 2013·British Journal of Cancer·R W F van LeeuwenF G A Jansman
Nov 23, 2007·Journal of Addictive Diseases·Mori J KrantzBecki Bucher Bartelson
Sep 10, 2009·Progress in Cardiovascular Nursing·Heather Carrier Milne, April Hazard Vallerand
Jan 4, 2013·International Journal of Clinical Pharmacy·Arjan BulsinkFrank G A Jansman
Aug 6, 2011·Healthcare Informatics Research·Man Young ParkRae Woong Park
Sep 3, 2011·Clinical Cardiology·Geneviève C DigbyAdrian Baranchuk
Apr 5, 2012·Clinical Pharmacology and Therapeutics·S PieningP G M Mol

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.